This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech

Galectin Drug is a Fatty Liver Flop

Galectin Drug is a Fatty Liver Flop

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

07/29/14 - 10:26 AM EDT

Galectin Pays Stock Promoters to Entice Retail Investors

Like Galena BioPharma and The DreamTeam Group, Galectin is also paying for a promotional campaign designed to entice retail investors into buying its stock.

07/28/14 - 12:34 PM EDT

Galectin Drug is a Fatty Liver Flop

Galectin Drug is a Fatty Liver Flop

Across just about every biomarker for efficacy Galectin thought to measure, GR-MD-02 showed no difference from placebo in a phase I study.

07/29/14 - 10:26 AM EDT

Why Gilead Sciences (GILD) Stock Is Up Today

Why Gilead Sciences (GILD) Stock Is Up Today

  • Tickers in this article:
  • GILD

Gilead Sciences (GILD) price target was raised to $127 by analysts at Maxim Group on Monday.

07/28/14 - 11:02 AM EDT

Amgen Shares Have the Right Prescription for Long-Term Growth

Amgen Shares Have the Right Prescription for Long-Term Growth

On the basis of improving cash flow and positive clinical trial data, these shares should reach $135 in the next six to 12 months.

07/28/14 - 12:06 PM EDT

CBS Binge-Buys Billboards, Puma Surges & Netflix Subscribers Soar

CBS Outdoor is buying over 1,100 billboards from rival Van Wagner for $690 million in cash.

07/25/14 - 06:00 AM EDT

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

FDA Rejects AcelRx Painkiller Dispensing Device (Update)

  • Tickers in this article:
  • ACRX

AcelRx believes it can gather all the requested information and re-submit Zalviso to the FDA before the end of the year.

07/28/14 - 09:44 AM EDT

Biotech Stock Mailbag: Intercept Pharma, Inovio

Biotech Stock Mailbag: Intercept Pharma, Inovio

  • Tickers in this article:
  • ICPT
  • INO

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

07/25/14 - 07:31 AM EDT

How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat?

How Will AbbVie (ABBV) Stock React To Its Second Quarter Earnings Beat?

  • Tickers in this article:
  • ABBV

AbbVie (ABBV) reported second quarter EPS and revenue well ahead of analysts expectations on Friday.

07/25/14 - 10:12 AM EDT

Gilead Sciences Beats Street and Sees Sovaldi Sales Double

  • Tickers in this article:
  • GILD

Gilead Sciences shares rose sharply in after-hours trading on Wednesday after the company reported second quarter results which surpassed analyst forecasts.

07/23/14 - 06:21 PM EDT

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

  • Tickers in this article:
  • GILD

In its first two quarters on the market, Sovaldi, a pill used to treat hepatitis C, has delivered $5.8 billion in revenue to Gilead. Remarkable.

07/23/14 - 05:44 PM EDT

How Will Gilead Sciences (GILD) Stock Be Affected By Its Second Quarter Earnings Results?

How Will Gilead Sciences (GILD) Stock Be Affected By Its Second Quarter Earnings Results?

  • Tickers in this article:
  • GILD

Gilead Sciences (GILD) beat analysts second quarter earnings estimates by 56 cents per share, posting an EPS of $2.36.

07/23/14 - 05:24 PM EDT

Intuitive Surgical Soars as Earnings Blow Past Expectations

  • Tickers in this article:
  • ISRG

Shares of Intuitive Surgical soared on Wednesday making it TheStreet's Move of the Day.

07/23/14 - 05:15 PM EDT

PTC Therapeutics CFO: Positive News on Translarna Just the Start

PTC Therapeutics expects conditional approval from European regulators this summer for its Duchenne muscular dystrophy (DMD) treatment Translarna.

07/23/14 - 04:38 PM EDT

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,890.50 -21.61 -0.13%
S&P 500 1,977.54 +7.59 0.39%
NASDAQ 4,474.0380 +31.34 0.71%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs